127 related articles for article (PubMed ID: 10088134)
1. Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
Breier A; Su TP; Malhotra AK; Elman I; Adler CM; Weisenfeld NI; Pickar D
Neuropsychopharmacology; 1999 Apr; 20(4):340-5. PubMed ID: 10088134
[TBL] [Abstract][Full Text] [Related]
2. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.
Breier A; Adler CM; Weisenfeld N; Su TP; Elman I; Picken L; Malhotra AK; Pickar D
Synapse; 1998 Jun; 29(2):142-7. PubMed ID: 9593104
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
4. Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes.
Reuss B; Unsicker K
Mol Cell Neurosci; 2001 Aug; 18(2):197-209. PubMed ID: 11520180
[TBL] [Abstract][Full Text] [Related]
5. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans.
Villemagne VL; Wong DF; Yokoi F; Stephane M; Rice KC; Matecka D; Clough DJ; Dannals RF; Rothman RB
Synapse; 1999 Sep; 33(4):268-73. PubMed ID: 10421707
[TBL] [Abstract][Full Text] [Related]
6. Clozapine blocks D-amphetamine-induced excitation of dopamine neurons in the ventral tegmental area.
Shi WX; Zhang XY; Pun CL; Bunney BS
Neuropsychopharmacology; 2007 Sep; 32(9):1922-8. PubMed ID: 17299514
[TBL] [Abstract][Full Text] [Related]
7. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
8. Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition.
Pedersen K; Simonsen M; Østergaard SD; Munk OL; Rosa-Neto P; Olsen AK; Jensen SB; Møller A; Cumming P
Neuroimage; 2007 Mar; 35(1):38-46. PubMed ID: 17223363
[TBL] [Abstract][Full Text] [Related]
9. Amphetamine pretreatment induces a change in both D2-Receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats.
Ginovart N; Wilson AA; Houle S; Kapur S
Biol Psychiatry; 2004 Jun; 55(12):1188-94. PubMed ID: 15184038
[TBL] [Abstract][Full Text] [Related]
10. Saturation of striatal D(2) dopamine receptors by clozapine.
Nyberg S; Chou YH; Halldin C
Int J Neuropsychopharmacol; 2002 Mar; 5(1):11-6. PubMed ID: 12057028
[TBL] [Abstract][Full Text] [Related]
11. Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study.
Soliman A; O'Driscoll GA; Pruessner J; Holahan AL; Boileau I; Gagnon D; Dagher A
Neuropsychopharmacology; 2008 Jul; 33(8):2033-41. PubMed ID: 17957215
[TBL] [Abstract][Full Text] [Related]
12. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.
Kegeles LS; Zea-Ponce Y; Abi-Dargham A; Rodenhiser J; Wang T; Weiss R; Van Heertum RL; Mann JJ; Laruelle M
Synapse; 1999 Mar; 31(4):302-8. PubMed ID: 10051112
[TBL] [Abstract][Full Text] [Related]
13. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
[TBL] [Abstract][Full Text] [Related]
14. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; O'Connell P; Davies N; Busatto GF; Costa DC; Murray RM; Ell PJ; Kerwin RW
Psychopharmacology (Berl); 1997 Mar; 130(2):152-8. PubMed ID: 9106913
[TBL] [Abstract][Full Text] [Related]
15. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
16. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.
Drevets WC; Gautier C; Price JC; Kupfer DJ; Kinahan PE; Grace AA; Price JL; Mathis CA
Biol Psychiatry; 2001 Jan; 49(2):81-96. PubMed ID: 11164755
[TBL] [Abstract][Full Text] [Related]
17. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
Hertel P; Nomikos GG; Svensson TH
Br J Pharmacol; 1997 Dec; 122(8):1639-46. PubMed ID: 9422809
[TBL] [Abstract][Full Text] [Related]
18. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine.
Oswald LM; Wong DF; McCaul M; Zhou Y; Kuwabara H; Choi L; Brasic J; Wand GS
Neuropsychopharmacology; 2005 Apr; 30(4):821-32. PubMed ID: 15702139
[TBL] [Abstract][Full Text] [Related]
19. Clozapine and olanzapine but not risperidone impair the pre-frontal striatal system in relation to egocentric spatial orientation in a Y-maze.
Castro CC; Dos Reis-Lunardelli EA; Schmidt WJ; Coitinho AS; Izquierdo I
Curr Neurovasc Res; 2007 Nov; 4(4):235-9. PubMed ID: 18045148
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
